Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer

Clinical Cancer Research

Volumn 11, Issue 4, 2005, Pages 1408-1415

  Gu, Jian ^a   Zhao, Hua ^a   Dinney, Colin P ^a   Zhu, Yong ^b   Leibovici, Dan ^a   Bermejo, Carlos E ^a   Grossman, H Barton ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; ASPARAGINE; ASPARTIC ACID; BCG VACCINE; GLUTAMINE; HISTIDINE; LYSINE; METHIONINE; PROLINE; VALINE;

ADULT; AGED; ALLELE; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CARCINOGENESIS; DNA POLYMORPHISM; DNA REPAIR; EXCISION REPAIR; FEMALE; GENE; GENE LOCUS; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MAMMAL CELL; NER GENE; PRIORITY JOURNAL; SURVIVAL TIME;

AGED; ALLELES; BCG VACCINE; DISEASE PROGRESSION; DNA HELICASES; DNA REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, GENETIC; SURVIVAL ANALYSIS; TIME FACTORS; URINARY BLADDER NEOPLASMS; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

EID: 14644437738     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1101     Document Type: Article

References (31)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Chopin DK, Gattegno B. Superficial bladder tumors. Eur Urol 2002;42:533-41.
3. Kurth K, Denis L, Sylvester R, de Pauw M. The natural history and the prognosis of treated superficial bladder cancer. EORTC GU group. Prog Clin Biol Res 1992;378:1-7.
4. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract 2002;10:311-22.
5. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000;163:73-8.
6. Merz VW, Marth D, Kraft R, Ackermann DK, Zingg EJ, Studer UE. Analysis of early failures after intravesical instillation therapy with Bacille Calmette-Guerin for carcinoma in situ of the bladder. Br J Urol 1995;75:180-4.
7. Schenk-Braat EAM, Bangma CH. Immunotherapy for superficial bladder cancer. Cancer Immunol Immunother 2004; [Epub ahead of print].
8. Helpap B, Schmitz-Drager BJ, Hamilton PW, et al. Molecular pathology of non-invasive urothelial carcinomas (part 1). Virchows Arch 2003;442:309-16.
9. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1513-30.
10. Amos CI, Xu W, Spitz MR. Is there a genetic basis for lung cancer susceptibility? Recent Results Cancer Res 1999;151:3-12.
11. Catto JW, Xinarianos G, Burton JL, Meuth M, Hamdy FC. Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. Int J Cancer 2003;105:484-90.
12. Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002;94:1091-9.
13. de Laat WL, Jaspers NG, Hoeijmakers JH. Molecular mechanism of nucleotide excision repair. Genes Dev 1999;13:768-85.
14. Wu X, Zhao H, Wei Q, et al. XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. Carcinogenesis 2003;24:505-9.
15. Marin MS, Lopez-Cima MF, Garcia-Castro L, Pascual T, Marron MG, Tardon A. Poly (AT) polymorphism in intron 11 of the XPC DNA repair gene enhances the risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2004;11:1788-93.
16. Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001;61:1354-7.
17. Volker M, Mone M, Karmakar P, et al. Sequential assembly of the nucleotide excision repair factors in vivo. Mol Cell 2001;8:213-24.
18. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594-601.
19. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004 Aug 1;10:4939-43.
20. Nagasubramanian R, Innocenti F, Ratain MJ. Pharmacogenetics in cancer treatment. Annu Rev Med 2003;54:437-52.
21. Bohle A, Brandau S. Immune mechanisms in Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003;170:964-9.
22. Nathan I, Dizdaroglu M, Bernstein L, et al. Induction of oxidative DNA damage in u937 cells by TNF or anti-Fas stimulation. Cytokine 2000;12:881-7.
23. Watanabe Y, Suzuki O, Haruyama T, Akaike T. Interferon-γ induces reactive oxygen species and endoplasmic reticulum stress at the hepatic apoptosis. J Cell Biochem 2003;89:244-53.
24. Pearl-Yafe M, Halperin D, Halevy A, Kalir H, Bielorai B, Fabian I. An oxidative mechanism of interferon induced priming of the Fas pathway in Fanconi anemia cells. Biochem Pharmacol 2003;65:833-42.
25. Mitropoulos D, Deliconstantinos G, Zervas A, Giannopoulos A, Kyriakou G, Dimopoulos C. Oxidative stress of red blood cells during Bacillus Calmette-Guerin intravesical instillations. In Vivo 2000;14:721-4.
26. Ueda S, Masutani H, Nakamura H, Tanaka T, Ueno M, Yodoi J. Redox control of cell death. Antioxid Redox Signal 2002;4:405-14.
27. Mitra S, Boldogh I, Izumi T, Hazra TK. Complexities of the DNA base excision repair pathway for repair of oxidative DNA damage. Environ Mol Mutagen 2001;38:180-90.
28. Reardon JT, Bessho T, Kung HC, Bolton PH, Sancar A. In vitro repair of oxidative DNA damage by human nucleotide excision repair system: possible explanation for neurodegeneration in xeroderma pigmentosum patients. Proc Natl Acad Sci U S A 1997;94:9463-8.
29. Gackowski D, Rozalski R, Roszkowski K, Jawien A, Foksinski M, Olinski R. 8-Oxo-7,8-dihydroguanine and 8-oxo-7,8-dihydro-2′-deoxyguanosine levels in human urine do not depend on diet. Free Radic Res 2001;35:825-32.
30. Kuraoka I, Bender C, Romieu A, Cadet J, Wood RD, Lindahl T. Removal of oxygen free-radical-induced 5′,8-purine cyclodeoxynucleosides from DNA by the nucleotide excision-repair pathway in human cells. Proc Natl Acad Sci U S A 2000;97:3832-7.
31. Licht CL, Stevnsner T, Bohr VA. Cockayne syndrome group B cellular and biochemical functions. Am J Hum Genet 2003;73:1217-39.